Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2022-01-01
Seri Bilgileri:Cancer Treatment and Research Communications
Konular:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
Online Erişim:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller